Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fipamezole for Neurogenic Orthostatic Hypotension in MSA or PD
NCT00758849Phase 2Unknown
- Sponsor
- Juvantia
- Start
- Sep 2008
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Neurogenic Orthostatic Hypotension (nOH) comparing Placebo with Fipamezole (2 arms). Primary endpoint: Blood pressure response to orthostatism at 28 days. Status: unknown.
02
Drugs
fipamezole
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on NCT00758849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00758849.